Article metrics
PDF
Other content recommended for you
- Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis
- Autologous haematopoietic stem cell transplantation for neurological diseases
- Haematopoietic stem cell transplantation in systemic sclerosis
- Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
- Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP
- Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis
- Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT
- Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation
- Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why?
- Current outlook of cardiac stem cell therapy towards a clinical application